Bio
I work as a Senior Director of Finance, working as the Finance Business Partner to the President of the Commercialisation & Outcomes service area (ICO), as well as to the President of the Analytics & Consulting (A&C) service area within ICON. I’ve been with ICON for over six years, having worked as a Controller before becoming Senior Director. I have over 20 years’ experience within finance and auditing and joined ICON back in 2008. In that time I’ve experienced some great development opportunities, including a course called 7 Habits of Highly Effective People, as well as a University College Dublin (UCD) International Business Management course in 2014. I’ve risen from Controller for Early Phase (US) to Global Controller for Early Phase (US and UK), before becoming the Senior Director in Business Planning.
In that time, I’ve witnessed the rapid growth of the company and have worked with a number of fantastic teams throughout the organisation. The growth of ICON has meant that my work is always changing, bringing new challenges – it keeps my line of work highly stimulating and has been great for my own development. I enjoy working for a company whose aim is the betterment of people’s lives – it adds that little bit extra motivation to everything I do!
Latest jobs
Life at ICON
.png)
Teaser label
Inside ICONContent type
BlogsPublish date
05/08/2025
Summary
Standing Strong on Ovarian Cancer Day: ICON's Commitment to Advancing Care Ovarian cancer remains one of the most challenging gynaecologic malignancies, both in terms of detection and treatmen
.png)
Teaser label
IndustryContent type
BlogsPublish date
05/07/2025
Summary
Patient Centricity in Clinical Research: What it is and Why it Matters In the past, clinical research was designed around the needs of sponsors, researchers, and regulatory bodies. Patients were of
.png)
Teaser label
IndustryContent type
BlogsPublish date
05/05/2025
Summary
Navigating Regulatory Landscapes: Comparing FDA, EMA, & MHRA in Clinical Trials In clinical research, no matter how promising a new therapy may be, it will go nowhere without regulatory appro
Recently viewed jobs